Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that, relative to their population size, New England states theoretically should support some of the largest markets for dyslipidemia drugs.

The new analytics tool from Decision Resources entitled PatientFinder: Dyslipidemia reveals that Massachusetts, Maine and Vermont have the highest percentage of untreated people with dyslipidemia who also have prescription (Rx) drug coverage. This potential is currently not being realized due to low treatment rates in these states. Massachusetts ranks 27th, Maine ranks 36th and Vermont ranks 40th in the percentage of their prevalent population that are currently receiving drug therapy for dyslipidemia. The result of this under-treatment is that significant opportunity remains for dyslipidemia market growth in each of these states. This type of information is invaluable to pharmaceutical companies who are challenged to pinpoint the areas of greatest need for their drugs.

Why Pharmaceutical Companies Need this Information

With the type of information included in PatientFinder, pharmaceutical organizations can identify the local markets that offer the greatest opportunity for their branded drug. Companies can identify markets that are underserved and determine if they should increase direct-to-consumer advertising, work with the local managed care organizations to increase awareness of the disease and benefits of their drug or align sales representatives to maximize market potential.

About PatientFinder

PatientFinder is the only healthcare analytics tool that assesses local markets for expansion opportunity by determining the number of insured patients in each territory who have the disease but are untreated. PatientFinder covers each of the 50 U.S. states and 318 U.S. metropolitan statistical areas (MSAs) and provides:

-- Disease-specific prevalence numbers for each U.S. state and MSA

-- Examination of treatment rates for the disease population to create percent treated and percent untreated estimates by state and MSA

-- Unique analysis of the untreated population examined through a filter of Rx benefit coverage. The end result is an estimate of how many patients are untreated but can afford therapy within each territory-the true local measure of opportunity for pharmaceutical companies

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

  All company, brand or product names contained in this document may be      trademarks or registered trademarks of their respective holders.     For more information, contact:     Elizabeth Marshall    Decision Resources    781-296-2563    emarshall@dresources.com 

First Call Analyst:
FCMN Contact:

SOURCE: Decision Resources

Contact: Elizabeth Marshall of Decision Resources, +1-781-296-2563,
emarshall@dresources.com

Usage of Ultrasound Contrast Agents in Echocardiography Declined in the Second Quarter of 2008

View Now